SOLARA - SOLARA ACTIVE PHARMA SCIENCES LIMITED Share Price

Management at Solara Active Pharma Sciences Limited provided a cautious outlook during the Q3 earnings call for FY '26. The company continues to face significant challenges in its ibuprofen business, which has historically been a core revenue driver. Currently, the ibuprofen division is struggling with a capacity utilization of only 3,000 tons out of 12,000 tons across two facilities, leading to substantial financial underperformance. The overall revenue for Q3 was reported at INR 346 crores, representing a 10% quarter-on-quarter growth; however, gross margins declined by 386 basis points to 47% due to the issues faced in the ibuprofen segment.

In detail, management noted that the non-ibuprofen business, which now comprises approximately 56% gross margins and 25% EBITDA, is seeing robust performance. This segment includes complex APIs and other niche products that command better pricing and profitability.

Key forward-looking points highlighted included:

1. An emphasis on the potential for the growth API business to become a significant driver of the overall company's performance.
2. The board has engaged external advisors to evaluate strategic options for the struggling ibuprofen business, promising further clarity by the Q4 results in April 2026.
3. Plans are in place to reduce operational costs and strategically reallocate resources from the underperforming ibuprofen segment to the growth area.
4. Management indicated that they have successfully reduced debt by INR 146 crores (approximately 19%) and aim to decrease it further to below INR 500 crores, bolstered by operational cash flows.

Overall, while the current business environment is challenging, especially within the ibuprofen segment, management remains optimistic about the growth prospects of their diversified API portfolio, focusing on sustainable, profitable growth.

Here are the major questions from the Q&A section of the earnings transcript along with detailed answers:

1. Question: "How do we ensure there is enough accountability or 'skin in the game' regarding the strategic advisors' recommendations on the ibuprofen business?"

   Answer: As Arun, I assure you that we focus on maximizing value for all stakeholders. We have an independent Board committee reviewing our options. The decisions will prioritize our customers and business health. Our analysis will determine the future direction of ibuprofen; derivatives remain profitable. We acknowledge the pressing need for strategic decisions due to current financial constraints.

2. Question: "Is there any scope for revival in the ibuprofen business, and what were its revenues and margins in FY '25?"

   Answer: We hope to provide specifics about ibuprofen's financials in our Q4 results. Currently, the business has challenges due to market pricing. Selling mainly to big pharma limits our competitiveness. Reviving this business hinges on thorough assessment and strategic decisions, focusing on the plain ibuprofen segment, which has seen profitability decline.

3. Question: "What is the current situation of the Vizag plant, and how will it be operational?"

   Answer: Currently, the Vizag plant is mothballed as we plan to transform it into a multipurpose facility. We're aiming to reconfigure it away from exclusive ibuprofen production, expanding to high-potency APIs and better utilizing our capabilities. We anticipate uncovering solutions during our review, with updates expected in Q4.

4. Question: "Will the sale of the ibuprofen business be considered as an option?"

   Answer: Potentially, yes. However, we are waiting for recommendations from our strategic advisors and will evaluate options thoroughly. Our findings will be disclosed alongside our Q4 results, ensuring careful consideration of all pathways before making any structural shifts.

5. Question: "Why were ibuprofen numbers not reported earlier as loss-making?"

   Answer: Previously, ibuprofen margins were viable, making earlier reporting unnecessary. Recent quarters exposed significant declines in profitability. Thus, it was crucial to inform you now, as the gross margins have suffered notably, reflecting changes in market dynamics.

6. Question: "How is R&D adjusting to maintain high margins in our portfolio?"

   Answer: R&D focus is shifting to support the broader portfolio with an emphasis on operational efficiencies. We're reviving dormant DMFs for profitable, niche APIs. Investments in R&D and new talent are underway to enhance our capabilities and adapt to market demands, particularly in high-margin segments.

7. Question: "What capacity utilization do we currently have for growth APIs?"

   Answer: We are operating at a capacity utilization of just over 70%. This level reinforces our capability to meet demand and align with revenue goals as we continue to optimize our operations.

8. Question: "Can you share growth targets for FY '27 within the API business?"

   Answer: We're not ready to provide specific growth guidance for FY '27 yet. This will be linked to our strategic decisions regarding ibuprofen, which are under evaluation. We'll provide further insights as our review processes progress.

9. Question: "What are the expectations for gross margins in the API business moving forward?"

   Answer: Margins appear stable in the 55%-56% range initially as we prioritize operational efficiencies. As we execute our strategies, we aim to enhance profitability, but for now, we advise adherence to these numbers.